BAUDAX BIO INC (BXRX) Stock Price, Quote, News and Overview
NASDAQ:BXRX - Nasdaq - US07160F4046 - Common Stock - Currency: USD
BXRX Quote, Performance and Key Statistics
0.1864
+0 (+0.59%)
The current stock price of BXRX is 0.1864 USD. In the past month the price decreased by -17.59%. In the past year, price decreased by -96.56%.
BXRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About BXRX
Company Profile
Baudax Bio, Inc. operates as a pharmaceutical company. The company is headquartered in Malvern, Pennsylvania and currently employs 9 full-time employees. The company went IPO on 2019-11-14. The firm is focused on developing and commercializing products for hospital and related acute care settings. The firm's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. The company is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. The company is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.
Company Info
BAUDAX BIO INC
490 Lapp Rd
Malvern PENNSYLVANIA 19355 US
CEO: Gerri A. Henwood
Employees: 9
Company Website: https://www.baudaxbio.com/
Phone: 14843952440.0
BAUDAX BIO INC / BXRX FAQ
What is the stock price of BAUDAX BIO INC today?
The current stock price of BXRX is 0.1864 USD. The price increased by 0.59% in the last trading session.
What is the ticker symbol for BAUDAX BIO INC stock?
The exchange symbol of BAUDAX BIO INC is BXRX and it is listed on the Nasdaq exchange.
On which exchange is BXRX stock listed?
BXRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BAUDAX BIO INC stock?
6 analysts have analysed BXRX and the average price target is 24.48 USD. This implies a price increase of 13033.05% is expected in the next year compared to the current price of 0.1864. Check the BAUDAX BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BAUDAX BIO INC worth?
BAUDAX BIO INC (BXRX) has a market capitalization of 1.71M USD. This makes BXRX a Nano Cap stock.
How many employees does BAUDAX BIO INC have?
BAUDAX BIO INC (BXRX) currently has 9 employees.
What are the support and resistance levels for BAUDAX BIO INC (BXRX) stock?
BAUDAX BIO INC (BXRX) has a support level at 0.17 and a resistance level at 0.2. Check the full technical report for a detailed analysis of BXRX support and resistance levels.
Is BAUDAX BIO INC (BXRX) expected to grow?
The Revenue of BAUDAX BIO INC (BXRX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the BXRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BAUDAX BIO INC (BXRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BXRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BXRX, evaluating the profitability, health, valuation and growth aspects
- BAUDAX BIO INC (BXRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BAUDAX BIO INC (BXRX) Sales and EPS estimates to see what analysts future expectations are.
- BAUDAX BIO INC (BXRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BAUDAX BIO INC (BXRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BAUDAX BIO INC (BXRX) Stock Chart to make your own analysis
- BAUDAX BIO INC (BXRX) Latest news and press-releases to stay up to date.
Does BAUDAX BIO INC (BXRX) stock pay dividends?
BXRX does not pay a dividend.
When does BAUDAX BIO INC (BXRX) report earnings?
BAUDAX BIO INC (BXRX) will report earnings on 2024-02-21, after the market close.
What is the Price/Earnings (PE) ratio of BAUDAX BIO INC (BXRX)?
BAUDAX BIO INC (BXRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-44.16).
BXRX Technical Analysis
BXRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BXRX. BXRX has a bad profitability rating. Also its financial health evaluation is rather negative.
BXRX Financial Highlights
Over the last trailing twelve months BXRX reported a non-GAAP Earnings per Share(EPS) of -44.16. The EPS increased by 7.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -161.54% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BXRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to BXRX. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 99.19% and a revenue growth -100% for BXRX